Company Overview - Stryker Corporation is represented by incoming CFO Preston Wells and VP of Finance, IR Jason Beach during Citi's 2025 Unplugged Medtech and Life Sciences Access Day [1]. Leadership Transition - Preston Wells acknowledges the challenge of stepping into a significant role but expresses confidence in the company's direction and vision [3]. - The company has well-defined targets and a clear vision for the future, indicating a strong leadership continuity under the guidance of Kevin and the existing leadership team [3]. Financial Goals - The company aims to maintain its trajectory in terms of top-line growth, operational margin, and earnings per share (EPS) goals [3].

Core Viewpoint - Stryker Corporation (SYK) has demonstrated strong performance in the medical technology sector, with significant growth driven by innovative products and robust demand across various segments, despite facing competitive pressures and a high valuation relative to the industry. Financial Performance - SYK's shares closed at $385.18, 5.2% below its 52-week high of $406.19, with a 13% gain over the past six months, outperforming Medtronic (MDT) but underperforming Boston Scientific (BSX) [1][3] - The company reported a strong fourth-quarter 2024 performance, with organic sales growth of 10.2%, driven by demand in Orthopaedics, MedSurg, and Neurotechnology [3][4] - Stryker achieved a 200-basis-point improvement in adjusted operating margin, reflecting effective pricing strategies and manufacturing efficiencies [4] Market Expansion and Innovation - Stryker is focusing on high-growth medical technology segments, including robotic-assisted surgery and advanced trauma solutions, which are expected to elevate its market growth [5][6] - The acquisition of Inari Medical allows Stryker to enter the $15 billion peripheral vascular market, enhancing its growth potential [7] - Stryker's R&D pipeline is strong, with upcoming product launches like Mako Spine and Mako Shoulder expected to drive future sales [8][9] Demand Drivers - Increased demand for capital equipment is supported by healthy hospital CapEx budgets, with strong sales in medical, instruments, and endoscopy divisions [13][14] - The rise in elective surgeries and the expansion of ambulatory surgery centers are critical growth drivers, with record highs in knee and hip surgeries performed in these settings [19][16] - Demographic trends, including an aging population, are contributing to increased demand for orthopedic and neurovascular interventions [18] Analyst Sentiment and Estimates - Analysts are bullish on Stryker's prospects, with sales and earnings expected to grow in the near term [20] - Zacks Consensus Estimates project sales of $24.47 billion for the current year, with an estimated year-over-year growth of 8.31% [22] - Earnings estimates for the current year are projected at $13.49 per share, reflecting a year-over-year growth of 10.66% [24] Valuation and Strategic Moves - SYK is currently trading at a forward P/E of 28.17X, above the industry average of 22.67X, indicating a stretched valuation [25] - The acquisition of Inari Medical is expected to boost sales by $590 million in the 2025 stub period, while divesting the Spinal Implant business may improve focus and profitability [29][30]

Core Insights - Stryker has launched the ProCeed hospital bed aimed at enhancing care efficiency and quality in markets outside the U.S. [1] - The ProCeed bed is designed to address the challenges of nursing staff turnover and shortages, providing a durable and easy-to-clean solution for healthcare environments [2] Product Features - The ProCeed bed includes design elements that prioritize safety for both patients and caregivers, such as a low bed height to aid patient mobility and reduce fall risks [3] - An innovative fifth wheel design reduces the push force required to move the bed, minimizing the risk of back injuries for caregivers [3] - The bed offers two headboard designs, one stationary and one mobile, which adjusts as the bed frame changes position [3] Company Overview - Stryker is recognized as a global leader in medical technologies, impacting over 150 million patients annually through innovative products and services in various medical fields [5]

Core Insights - Stryker will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on February 27, 2025 [1] - The presentation by Stryker's management is scheduled for 12:15 p.m. Eastern Time [1] - A simultaneous webcast and replay of the presentation will be available on Stryker's website [2] Company Overview - Stryker is a global leader in medical technologies, focusing on improving healthcare through innovative products and services [3] - The company operates in MedSurg, Neurotechnology, and Orthopaedics, impacting over 150 million patients annually [3] - More information about Stryker can be found on their official website [3]

Core Insights - Stryker will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on February 27, 2025 [1] - The presentation by Stryker's management is scheduled for 12:15 p.m. Eastern Time [1] - A simultaneous webcast and replay of the presentation will be available on Stryker's website [2] Company Overview - Stryker is a global leader in medical technologies, focusing on improving healthcare outcomes [3] - The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3] - Stryker impacts more than 150 million patients annually [3] Contact Information - For investor inquiries, contact Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com [4] - For media inquiries, contact Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or yin.becker@stryker.com [4]

Financial Performance - In 2024, Stryker Corporation achieved reported net sales growth of 10.2%, with net sales totaling $22,595 million[141]. - The company reported net earnings of $2,993 million, resulting in net earnings per diluted share of $7.76, a decrease of 5.9% compared to 2023[144]. - Adjusted net earnings per diluted share increased by 15.0% to $12.19, up from $10.60 in 2023[144]. - Gross profit increased to $14,440 million in 2024, with a gross profit margin of 63.9%, up from 63.7% in 2023 and 62.8% in 2022, driven by higher sales pricing and favorable volume[152][154][155]. - Operating income was $3,689 million in 2024, with an operating income margin of 16.3%, down from 19.0% in 2023 but up from 15.4% in 2022[164]. - Comprehensive income for 2024 was $3,116 million, compared to $2,970 million in 2023, showing an increase in overall financial performance[245]. - Net earnings for 2024 decreased to $2,993 million or $7.76 per diluted share, down from $3,165 million or $8.25 per diluted share in 2023[173]. Sales and Revenue - MedSurg and Neurotechnology net sales increased by 11.1% to $13,518 million, while Orthopaedics net sales grew by 8.9% to $9,077 million[145]. - Net sales for 2024 reached $22,595 million, an increase of 10.7% from $20,498 million in 2023[243]. - Neuro Cranial sales for 2024 were $2,136 million, a 13.9% increase from $1,876 million in 2023[306]. - Excluding acquisitions and divestitures, net sales in constant currency increased by 9.1% due to higher unit volume and 1.1% from price increases[146]. Expenses and Costs - Research, development and engineering expenses as a percentage of net sales decreased to 6.5% in 2024 from 6.8% in 2023, primarily due to lower spending on medical device regulations in the European Union[157]. - Selling, general and administrative expenses as a percentage of net sales decreased to 34.0% in 2024 from 34.7% in 2023, attributed to continued spend discipline and lower charges for structural optimization[159]. - Research, development, and engineering expenses increased to $1,466 million in 2024 from $1,388 million in 2023, indicating a focus on innovation[243]. Cash Flow and Investments - Cash provided by operating activities in 2024 was $4,242 million, compared to $3,711 million in 2023, marking a 14.3% increase[186]. - Cash used in investing activities was $3,000 million in 2024, significantly higher than $962 million in 2023, primarily due to acquisitions[188]. - Cash used in financing activities decreased to $525 million in 2024 from $1,594 million in 2023, driven by lower debt repayments[189]. - Total cash and cash equivalents increased by $681 million in 2024, compared to an increase of $1,127 million in 2023[184]. Acquisitions and Capital Allocation - Stryker invested $1,628 million in acquisitions and paid $1,219 million in dividends to shareholders in 2024[141]. - In 2024, Stryker completed various acquisitions with total consideration of $1,628 million, plus $400 million contingent on achieving certain milestones[142]. - The company plans to utilize excess operating cash for acquisitions, dividends, and share repurchases as part of its capital allocation strategy[185]. - Goodwill attributable to acquisitions in 2024 amounted to $1.154 billion, reflecting strategic benefits and market expansion[331]. Debt and Liabilities - The company repaid $600 million of senior unsecured notes in May 2024 and issued new senior unsecured notes totaling $2,100 million in September 2024[143]. - Long-term debt, excluding current maturities, increased to $12,188 million in 2024 from $10,901 million in 2023, an increase of 11.8%[248]. - Total contractual obligations are projected to be $21,187 million, with $4,801 million due in 2025[198]. Impairments and Taxation - Goodwill impairment charges of $456 million were recorded in 2024 related to the Spine business[162]. - The effective tax rate was 14.3% in 2024, an increase from 13.8% in 2023, influenced by deferred tax benefits related to the anticipated sale of the Spinal Implants business[171]. - Goodwill and other impairments in 2024 amounted to $977 million, a significant increase from $36 million in 2023[181]. Assets and Equity - Total assets increased to $42,971 million in 2024, up from $39,912 million in 2023, representing a growth of 5.2%[248]. - Total shareholders' equity rose to $20,634 million in 2024, up from $18,593 million in 2023, indicating an increase of 11%[251]. - Current assets exceeded current liabilities by $7,231 million in 2024, up from $4,597 million in 2023, showing a significant improvement in liquidity[192]. Currency and Foreign Exchange - The company experienced a 0.5% negative impact on net sales due to foreign currency exchange rates in 2024[146]. - A hypothetical 10% change in foreign currencies relative to the United States Dollar would change the fair value of derivative instruments by approximately $489 million[228]. - The company recognized a total of $106 million in currency exchange rate gains in net earnings for 2024, an increase from $98 million in 2023[326]. Legal and Regulatory Matters - The company is currently involved in investigations regarding potential violations of the FCPA, cooperating with regulatory authorities[336]. - The company recorded charges of $17 million related to ongoing legal claims in 2024, with an accrual of $202 million at year-end[338].

Portage, Michigan, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 14 years of distinguished service, Allan Golston has notified the company that he will not stand for re-election at Stryker's 2025 Annual Meeting of Shareholders, which is expected to be held on May 8, 2025. Golston joined Stryker’s Board of Directors in 2011 and served as independent Lead Director from 2016 to 2022. He also served on the Governance and Nominating Committee and as Chair of the Compensation and ...

Portage, Michigan, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable April 30, 2025 to shareholders of record at the close of business on March 31, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Wall Street analysts rerated Stryker Corp SYK Wednesday after the company’s fourth-quarter print.Stryker reported quarterly earnings of $4.01 per share, which beat the analyst consensus estimate of $3.87. The company reported quarterly sales of $6.44 billion, up by 10.7%, which beat the analyst consensus estimate of $6.36 billion.Also Read: Nasdaq Touts 10% Revenue Growth In Q4, Sets 2025 Expense And Tax GuidanceSeveral analysts rerated the stock:Stifel analyst Rick Wise maintained Stryker with a Buy and ra ...